The present invention relates to methods for assessing binding agent specificity, in particular antibody specificity. The present invention thus provides a method of analysing a mixture of polypeptides comprising the steps of: (i) separating the polypeptides in the mixture into a plurality of fractions; (ii) contacting a first aliquot of two or more of the fractions with a plurality of different binding agents attached to one or more solid supports and detecting the binding of the polypeptides to the binding agents in each fraction; (iii) assessing the amino acid composition of the polypeptides in a second aliquot of said fractions by mass spectrometry; and (iv) correlating the binding results detected in step (ii) and the mass spectrometry results from step (iii) to assess the specificity of the binding agents for a polypeptide of interest.

The present invention relates to methods for assessing binding agent specificity, in particular antibody specificity. The present invention thus provides a method of analysing a mixture of polypeptides comprising the steps of: (i) separating the polypeptides in the mixture into a plurality of fractions; (ii) contacting a first aliquot of two or more of the fractions with a plurality of different binding agents attached to one or more solid supports and detecting the binding of the polypeptides to the binding agents in each fraction; (iii) assessing the amino acid composition of the polypeptides in a second aliquot of said fractions by mass spectrometry; and (iv) correlating the binding results detected in step (ii) and the mass spectrometry results from step (iii) to assess the specificity of the binding agents for a polypeptide of interest.

The present invention relates to a new class of steroid saponins that have interesting biological activity. In particular the present invention relates to a class of steroid saponins in which the sugar moiety has been selectively functionalised to introduce a moiety that contains either, (i) a hydrogen ion donor, (ii) a hydrogen ion acceptor or (iii) a combination thereof. These new, water-soluble compounds are found to not only have potent anti-cancer properties per se but also have the ability to promote the immune response in a subject and can thus act as adjuvants for T-cell activation in cancer therapy.

Chemical entities that are novel compounds, pharmaceutical compositions and methods of treatment of cancer are described.

Chemical entities that are novel compounds, pharmaceutical compositions and methods of treatment of cancer are described.

The present application relates to methods for treating and/or preventing prion diseases and/or brain diseases, disorders or conditions that benefit from reduced levels of the cellular prion protein (PrPC) and/or altered levels of NKA alpha subunits comprising administering and effective amount of one or more agents that alter levels of one or more NKA alpha subunits, in a subject in need thereof, wherein each NKA alpha subunit with altered levels is a different paralog. The one or more agents are, for example, one or more compounds of Formula I, or a pharmaceutically acceptable salt and/or solvate thereof.

##STR00001##

Chemical entities that are novel compounds, pharmaceutical compositions and methods of treatment of cancer are described.

Chemical entities that are novel compounds, pharmaceutical compositions and methods of treatment of cancer are described.

A resist composition containing a compound (B1) represented by Formula (b1) in which R.sup.b1 represents a monovalent hydrocarbon group which has a steroid skeleton and 17 to 50 carbon atoms, Y.sup.b1 and Y.sup.b2 each independently represent a divalent linking group having a hetero atom, V.sup.b1 represents a divalent linking group containing a cyclic aliphatic hydrocarbon group, V.sup.b2 represents an alkylene group, a fluorinated alkylene group, or a single bond, R.sup.f1 represents a hydrogen atom, a fluorine atom, or a fluorinated alkyl group having 1 to 5 carbon atoms, m represents an integer of 1 or greater, and M.sup.m+ represents an m-valent organic cation

##STR00001##

A resist composition containing a compound (B1) represented by Formula (b1) in which R.sup.b1 represents a monovalent hydrocarbon group which has a steroid skeleton and 17 to 50 carbon atoms, Y.sup.b1 and Y.sup.b2 each independently represent a divalent linking group having a hetero atom, V.sup.b1 represents a divalent linking group containing a cyclic aliphatic hydrocarbon group, V.sup.b2 represents an alkylene group, a fluorinated alkylene group, or a single bond, R.sup.f1 represents a hydrogen atom, a fluorine atom, or a fluorinated alkyl group having 1 to 5 carbon atoms, m represents an integer of 1 or greater, and M.sup.m+ represents an m-valent organic cation

##STR00001##